Article info

Download PDFPDF

Clinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early disease

Authors

  • Josef S Smolen Department of Internal Medicine III, Hietzing Hospital, Vienna, Austria Division of Rheumatology, Medical University Vienna, Vienna, Austria PubMed articlesGoogle scholar articles
  • Sabine Collaud Basset TRB Chemedica International SA, Geneva, Switzerland PubMed articlesGoogle scholar articles
  • Maarten Boers Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, The Netherlands Amsterdam Rheumatology and Immunology Center, Amsterdam, The Netherlands PubMed articlesGoogle scholar articles
  • Ferdinand Breedveld Leiden University Medical Centre, Leiden, The Netherlands PubMed articlesGoogle scholar articles
  • Christopher J Edwards Musculoskeletal Research Unit, NIHR Wellcome Trust Clinical Research Facility, University Hospital Southampton, Southampton, UK PubMed articlesGoogle scholar articles
  • Tore K Kvien Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway PubMed articlesGoogle scholar articles
  • Pierre Miossec Department of Clinical Immunology and Rheumatology, Immunogenomics and Inflammation Research Unit EA 4130, University of Lyon 1, Edouard Herriot Hospital, Lyon, France PubMed articlesGoogle scholar articles
  • Tuulikki Sokka-Isler Faculty of Health Sciences, University of Eastern Finland, Jyvaskyla Central Hospital, Jyvaskyla, Finland PubMed articlesGoogle scholar articles
  • Ronald F van Vollenhoven Amsterdam Rheumatology and Immunology Center, Amsterdam, The Netherlands Department of Clinical Immunology and Rheumatology, Academic Medical Center, Amsterdam, The Netherlands Department of Rheumatology, VU University Medical Centre, Amsterdam, The Netherlands PubMed articlesGoogle scholar articles
  • Eric C Abadie Euremed Consulting, Paris, France Universidade de Lisboa, Lisbon, Portugal PubMed articlesGoogle scholar articles
  • Olivier Bruyère Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium PubMed articlesGoogle scholar articles
  • Cyrus Cooper MRC Lifecourse Epidemiology Unit, NIHR Nutrition Biomedical Research Centre, University of Southampton, Southampton, UK NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK Oxford NIHR Musculoskeletal Biomedical Research Unit, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, The Botnar Research Centre, University of Oxford, Oxford, UK PubMed articlesGoogle scholar articles
  • Heidi Mäkinen Rheumatology Department, Tampere University Hospital, Tampere, Finland PubMed articlesGoogle scholar articles
  • Thierry Thomas Rheumatology Department, University Hospital of Saint-Etienne, Saint-Etienne, France INSERM U1059, Université de Lyon, Lyon, France PubMed articlesGoogle scholar articles
  • Peter Tugwell Department of Medicine, University of Ottawa, Ottawa, Canada PubMed articlesGoogle scholar articles
  • Jean-Yves Reginster Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium PubMed articlesGoogle scholar articles
  1. Correspondence to Professor Josef S Smolen, Division of Rheumatology, Medical University Vienna, Waehringer Guertel 18-20, Vienna 1090, Austria; josef.smolen{at}wienkav.at
View Full Text

Citation

Smolen JS, Collaud Basset S, Boers M on behalf of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), et al
Clinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early disease

Publication history

  • Received February 23, 2016
  • Accepted March 12, 2016
  • First published April 1, 2016.
Online issue publication 
June 10, 2016

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.